B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on TG Therapeutics (NASDAQ:TGTX) on Thursday, setting a price target of $91, which is approximately 112.97% above the present share price of $42.73.
Mamtani expects TG Therapeutics to post earnings per share (EPS) of $0.00 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in TG Therapeutics, with an average price target of $75.75.
The analysts price targets range from a high of $91 to a low of $63.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $38 thousand and a net profit of -$86.78 million. The company's market cap is $5.89 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 32.3% and a 54.29% success rate.
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.